FY2024 Earnings Estimate for ARCT Issued By Leerink Partnrs

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for shares of Arcturus Therapeutics in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo now forecasts that the biotechnology company will post earnings per share of ($2.55) for the year, up from their prior estimate of ($3.00). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.80) EPS and Q4 2025 earnings at ($0.79) EPS.

ARCT has been the subject of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $17.42 on Friday. The stock’s 50 day simple moving average is $17.27 and its 200 day simple moving average is $19.74. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00. The firm has a market cap of $471.91 million, a PE ratio of -7.85 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the prior year, the company posted ($0.61) EPS.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ARCT. Point72 DIFC Ltd acquired a new stake in shares of Arcturus Therapeutics in the second quarter valued at approximately $188,000. Squarepoint Ops LLC acquired a new stake in shares of Arcturus Therapeutics during the 2nd quarter valued at $718,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics during the second quarter worth about $142,000. Deerfield Management Company L.P. Series C bought a new position in shares of Arcturus Therapeutics during the second quarter valued at $958,000. Finally, Millennium Management LLC grew its position in shares of Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after buying an additional 396,505 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.